On September 25, 2023 Askat reported the termination of a license agreement for AAT-007 & AAT-008 (EP4 Antagonist) for global immuno-oncology as of March 20, 2024, which was originally signed with Ikena Oncology Inc (Headquarters: Massachusetts, USA; hereinafter referred to as "Ikena") on December 14, 2017 (Press release, AskAt, SEP 25, 2023, View Source [SID1234635375]). Clinical trials have shown that AAT-007 was effective and well tolerated in microsatellite stable colorectal cancer, as previously announced (View Source),. This termination is due to a change in Ikena’s R&D strategy. AskAt will continue to implement strategic options for AAT-007 and AAT-008, including the selection of a new partner.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!